Company profile

Future of Boston Scientific

#
Rank
24
| Quantumrun Global 1000

Boston Scientific Corporation (Simply known as Boston Scientific) is a global developer, producer and marketer of medical devices whose products are used in various interventional medical specialties, including gynecology, oncology, vascular surgery, electrophysiology, neuromodulation, interventional cardiology, interventional radiology, peripheral interventions, neurovascular intervention, cardiac surgery, endoscopy, and urology.

Home Country:
Sector:
Industry:
Medical Products and Equipment
Founded:
1979
Global employee count:
27000
Domestic employee count:
13000
Number of domestic locations:
9

Financial Health

Revenue:
$8386000000 USD
3y average revenue:
$7747666667 USD
Operating expenses:
$5515000000 USD
3y average expenses:
$5539000000 USD
Funds in reserve:
$196000000 USD
Market country
Revenue from country
0.57
Market country
Revenue from country
0.09

Asset Performance

  1. Product/Service/Dept. name
    Interventional cadiology
    Product/Service revenue
    2240000000
  2. Product/Service/Dept. name
    Cardiac rhythm management
    Product/Service revenue
    1930000000
  3. Product/Service/Dept. name
    Endoscopy
    Product/Service revenue
    1420000000

Innovation assets and Pipeline

Investment into R&D:
$880000000 USD
Total patents held:
4825
Number of patents field last year:
129

All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page. 

DISRUPTION VULNERABILITY

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations. However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.

*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.

*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.

*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.

*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.

*3D printing (additive manufacturing) will increasingly work in tandem with future automated manufacturing plants to drive down the costs of production for medical equipment even further by the early 2030s.

COMPANY’S FUTURE PROSPECTS

Company Headlines